New fusion protein treatment holds promise for ‘royal’ blood clotting disorder

Science ◽  
2020 ◽  
Author(s):  
Rebekah Tuchscherer
Keyword(s):  
Fusion Protein ◽  
Blood Clotting ◽  
Clotting Disorder ◽  
Protein Treatment

Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy

2005 ◽  
Vol 11 (23) ◽  
pp. 8492-8502 ◽  
Author(s):  
Aihong Liu ◽  
Peisheng Hu ◽  
Leslie A. Khawli ◽  
Alan L. Epstein
Keyword(s):  
Fusion Protein ◽  
Treg Cell ◽  
Cell Depletion ◽  
Fc Fusion Protein ◽  
Protein Treatment

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema

2008 ◽  
Vol 122 (2) ◽  
pp. 423-424 ◽  
Author(s):  
Dagmar Simon ◽  
Jennifer Wittwer ◽  
Ganna Kostylina ◽  
Urs Buettiker ◽  
Hans-Uwe Simon ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Atopic Eczema ◽  
Lymphocyte Function ◽  
Protein Treatment

New Treatment for Rare Blood Clotting Disorder

JAMA ◽  
2019 ◽  
Vol 321 (11) ◽  
pp. 1042
Author(s):  
Feyza Sancar
Keyword(s):  
Blood Clotting ◽  
New Treatment ◽  
Clotting Disorder

scholarly journals Intragenic Factor IX restriction site polymorphism in hemophilia B variants

Blood ◽  
1985 ◽  
Vol 65 (2) ◽  
pp. 441-443 ◽  
Author(s):  
HJ Hassan ◽  
M Orlando ◽  
A Leonardi ◽  
C Chelucci ◽  
R Guerriero ◽  
...  
Keyword(s):  
Genomic Dna ◽  
Blood Clotting ◽  
Restriction Site ◽  
Wide Spectrum ◽  
Normal Subjects ◽  
Polymorphic Site ◽  
Factor Ix ◽  
Hemophilia B ◽  
Coagulant Activity ◽  
Clotting Disorder

Abstract This study includes 47 normal subjects and 25 hemophilia B patients without inhibitor(s), showing different factor IX coagulant activity and antigen levels. Genomic DNA, digested with various restriction endonucleases, was hybridized with two different factor IX probes, ie, the cDNA and the subgenomic probe for the intragenic TaqI polymorphic site. cDNA restriction patterns suggest absence of gross rearrangements and/or deletions in all hemophilic patients. The frequency of the X chromosome bearing the TaqI polymorphic site is 0.32 +/- 0.09 in hemophilic subjects v 0.36 +/- 0.06 in normal control subjects, the latter value being comparable to that reported for the normal British population. No association between this polymorphism and hemophilia B variants has been observed, thus indicating that a wide spectrum of mutations underlies this blood-clotting disorder and particularly each of its variants.

scholarly journals Human Relaxin‐2 Fusion Protein Treatment Prevents and Reverses Isoproterenol‐Induced Hypertrophy and Fibrosis in Mouse Heart

2019 ◽  
Vol 8 (24) ◽  
Author(s):  
Junhui Sun ◽  
Weidong Hao ◽  
Natasha Fillmore ◽  
Hanley Ma ◽  
Danielle Springer ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Mouse Heart ◽  
Relaxin 2 ◽  
Protein Treatment
Sign in / Sign up

Export Citation Format

Share Document